Data Update 7 for 2025: The End Game in Business!
I am in the third week of the corporate finance class that I teach at NYU Stern, and my students have been lulled into a false sense of complacency about what’s coming, since I have not used a single metric or number in my class yet. In fact, we have spent almost four sessions (that is 15% of the overall class) talking about the end game in business. In an age when ESG, sustainability and stakeholder wealth maximization have all tried to elbow their way to the front of the line, all laying claim to being what business should be about, I have burnished my “moral troglodyte” standing by sticking with my belief that the end game in business is to maximize value, with earnings and cash flows driving that value, and that businesses that are profitable and value creating are in a much better position to do good, if they choose to try. In this post, I will focus on how companies around the world, and in different sectors, performed on their end game of delivering profits, by first focusing on profitability differences across businesses, then converting profitability into returns, and comparing these returns to the hurdle rates that I talked about in my last data update post.
Profitability – Absolute and Relative
While we may all agree with the proverbial bottom line being profits, there seems to be no consensus on how best to measure profitability, either from an accounting or an economic perspective. In this section, I will begin with a simplistic breakdown of the income statement, the financial statement that is supposed to tell us how much a business generated in profits in during a period, and use it as an (imperfect) tool to understand the business economics.
While accountants remain focused on balance sheets, with a fixation of bringing intangibles on to the balance and marking everything up to the market, much of the information that we need to assess the value of a business comes from income and cash flow statements. I am not an accountant, but I do rely on accounting statements for the raw data that I use in corporate finance and valuation. I have tried my hand at financial statement analysis, as practiced by accountants, and discovered that for the most part, the analysis creates more confusions than clarity, as a multiplicity of ratios pull you in different directions. It is for that reason that I created my own version of an accounting class, that you can find on my webpage.
During the course of the class, I assess the income statement, in its most general form, by looking at the multiple measures of earnings at different phases of the statement:
- To get from net income to earnings per share, you bring in share count, and actions taken by companies that alter that share count will have effects. Thus, a company that issues new shares to fund its growth may see net income growth, but its earnings per share growth will lag, as the share count increases. Conversely, a company that buys back shares will see share count drop, and earnings per share growth will outpace net income growth.
- To get from operating income to net income, you have multiple variables to control for. The first is taxes, and incorporating its effect will generally lead to lower net income, and the tax rate that you pay to get from pretax profit to net income is the effective tax rate. To the extent that you have cash on your balance, you will generate interest income which adds on to net income, but interest expenses on debt will reduce income, with the net effect being positive for companies with large cash balance, relative to the debt that they owe, and negative for firms with large net debt outstanding. There is also the twist of small (minority) holdings in other companies and the income you generate from those holdings that affect net income.
- To get from gross income to operating income, you have to bring in operating expenses that are not directly tied to sales. Thus, if you have substantial general and administrative costs or incur large selling and advertising costs or if you spend money on R&D (which accountants mistakenly still treat as operating expenses), your operating income will be lower than your gross income.
- Finally, to get from revenues to gross income, you net out the expenses incurred on producing the goods/services that you sell, with these expenses often bundled into a “cost of goods sold” categorization. While depreciation of capital investments made is usually separated out from costs of goods sold, and shown as an operating cost, there are some companies, where it is bundled into costs of goods sold. In many cases, the only statement where you will see depreciation and amortization as a line item is the statement of cash flows.
With that template in place, the place to start the assessment of corporate profitability is to to look at how much companies generated in each of the different earnings metrics around the world in 2024, broken down by sector:
- On a net profit basis, there is no contest for the sector that delivers the most net income. It is financials by a wide margin, accounting for a third of the net profits generated by all firms globally in 2024. In fact, technology, which is the sector with the highest market cap in 2024, is third on the list, with industrials taking second place.
- As you move from down the income statement, the percentage of firms that report negative earnings decreases. Across the globe, close to 84% of firms had positive gross profits, but that drops to 67% with EBITDA, 62% percent with operating income and 61% with net income.
- Across sectors, health care has the highest percentage of money-losing companies, on every single metric, followed by materials and communication services, whereas utilities had the highest percentage of money makers.
With the caveat that accounting choices can affect these margins, you can see that the rankings do make intuitive sense. The list of industry groups that have the highest margins are disproportionately in technology, though infrastructure firms (oil and gas, green energy, telecom) also make the list since their investment is up front and not per added product sold. The list of industry group with the lowest margins are heavily tilted towards manufacturing and retail, the former because of the costs of making their products and the latter because of their intermediary status.
Accounting Returns
While scaling profits to revenues to get margins provides valuable information about business models and their efficacy, scaling profits to capital invested in a business is a useful tool for assessing the efficiency of capital allocation at the business., The two measures of profits from the previous section that are scaled to capital are operating income (before and after taxes) and net income, with the former measured against total invested capital (from equity and debt) and the latter against just equity capital. Using a financial balance sheet structure again, here is what we get:
The achilles heel for accounting return measures is their almost total dependence on accounting numbers, with operating (net) income coming from income statements and invested capital (equity) from accounting balance sheets. Any systematic mistakes that accountants make (such as not treating leases as debt, which was the default until 2019, and treating R&D as an operating expense, which is still the case) will skew accounting returns. In addition, accounting decisions to write off an asset or take restructuring charges will make the calculation of invested capital more difficult. I wrote a long (and boring) paper on the mechanics of computing accounting returns laying out these and other challenges in computing accounting returns, and you are welcome to browse through it, if you want.
If you are willing to live with the limitations, the accounting returns become proxies for what a business earns on its equity (with return on equity) and as a business (with the cost of capital). Since the essence of creating value is that you need to earn more than your cost of capital, you can synthesize returns with the costs of equity and capital that I talked about in the last post, to get measures of excess returns:
![]() |
Excess returns by industry: US, Global, Emerging Markets, Europe, Japan, India and China |
- Making money is not enough for success: In many businesses, public or private, managers and even owners seem to think that making money (having a positive profit) represents success, not recognizing that the capital invested in these businesses could have been invested elsewhere to earn returns.
- Corporate governance is a necessity; Marty Lipton, a renowned corporate lawyer and critic of this things activist argued that activist investing was not necessary because most companies were well managed, and did not need prodding to make the right choices. The data in this post suggests otherwise, with most companies needing reminders from outside investors about the opportunity cost of capital.
- Companies are not fatted calves: In the last few years, two groups of people have targeted companies – politicians arguing that companies are price-gouging and the virtue crowd (ESG, sustainability and stakeholder wealth maximizers) pushing for companies to spend more on making the world a better place. Implicit in the arguments made by both groups is the assumption that companies are, at least collectively, are immensely profitable and that they can afford to share some of those spoils with other stakeholders (cutting prices for customers with the first group and spending lavishly on advancing social agendas with the second). That may be true for a subset of firms, but for most companies, making money has only become more difficult over the decades, and making enough money to cover the cost of the capital that they raise to create their businesses is an even harder reach. Asking these already stretched companies to spend more money to make the world a better place will only add to the likelihood that they will snap, under the pressures.
- Data Update 1 for 2025: The Draw (and Danger) of Data!
- Data Update 2 for 2025: The Party continued for US Equities
- Data Update 3 for 2025: The times they are a’changin’!
- Data Update 4 for 2025: Interest Rates, Inflation and Central Banks!
- Data Update 5 for 2025: It’s a small world, after all!
- Data Update 6 for 2025: From Macro to Micro – The Hurdle Rate Question!
- Data Update 7 for 2025: The End Game in Business!
Source: https://aswathdamodaran.blogspot.com/2025/02/data-update-7-for-2025-end-game-in.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
![Report abuse](/img/report_abuse.png)